Candelasa, Cleofe H.

HRN: 21-37-03  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/22/2022
CEFUROXIME 1.5GM (VIAL)
05/23/2022
05/23/2022
IV
1.5gm
1 Dose
Loading Dose For TAHBSO W/ VAGINAL MYOMECTOMY
Waiting Final Action 
05/23/2022
CEFUROXIME 1.5GM (VIAL)
05/23/2022
05/24/2022
IVT
1.5gm
Q8 X 3 Doses
Post-op TAHBSO
Waiting Final Action 
05/24/2022
MUPIROCIN 2%, 15G (TUBE)
05/24/2022
05/30/2022
TOPICAL
15gm
OD
S/P TAHBSO
Waiting Final Action 
05/24/2022
CEFUROXIME 500MG (TAB)
05/24/2022
05/30/2022
ORAL
500mg
BID
S/P TAHBSO
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: